Therapeutic options to prevent further vascular occlusion are varied and may involve antithrombotic agents alone or in combination with steroid immunosuppression to modulate the prothrombotic effect of the antibodies, and aggressive therapy with both modalities has been recommended for younger patients?-4 It is recommended that anticoagulation be continued until 6 months after the disappearance of the antibody?
Given the lack of a consistent response to a specific therapy in the antiphospholipid syndrome and the possibility of future pregnancy, this patient was initially treated with oral prednisolone and with aspirin rather than intensive warfarin treatment (INR>3)?, 4 , l O During 14 months of treatment she has had one further BRAo. In the light of experience with this case we would now anticoagulate with warfarin all patients with antiphospholipid syndrome and recurrent retinal vascular occlusion, and we would continue treatment indefinitely.
Sir, Unfortunately, there was no visual recovery in either eye. The patient has been followed up for 18 months. He has a visual acuity of 6/6 in both eyes, atrophy of the upper halves of both optic discs and bilateral non progressive inferior altitudinal field defects. 
Discussion
The clinical picture, including angiographic changes, is one of bilateral anterior ischaemic optic neuropathy (AlON). The age of the patient, the lack of systemic symptoms, the relatively mild visual loss and the normal erythrocyte sedimentation rate and C-reactive protein level exclude an arteritic form of AlON. The non-arteritic form of AlON can occur in diabetes mellitus, uraemia, following cataract extraction, following acute blood loss and in the collagen disorders. None of these situations applies to our patient. We could find no reports of AION following bumetanide or captopril. Papilloedema as a result of pseudotumour cerebri and optic neuropathy' has been reported 2 •3 in patients taking amiodarone. The features of amiodarone-induced optic neuropathy are: relatively well preserved visual function, reversibility on discontinuation and the absence of the characteristic crowding of the optic disc that predisposes to non-arteritic AION. Multi-lamellar inclusion bodies, typical of genetic and drug-induced lipidosis, have been demonstrated in the large axons of the retrobulbar optic nerve from an asymptomatic patient. 4 Amiodarone also generates free radicals in vitro and in vivo, S which again may result in neurotoxicity. A leucocytoclastic vasculitis and/ or endothelial injurl· 7 affecting the posterior ciliary circulation may result in AION rather than an optic neuropathy. Sedwick 1 described a 62-year-old woman with hypertension and diabetes mellitus, taking amiodarone, who developed sequential non-arteritic AION, the visual loss continuing despite stopping the drug. Our patient has fairly similar features (including the presence of hypertrophic cardiomyopathy), although the visual acuity has been well maintained with no stepwise or gradual deterioration as seen in classic non arteritic AION.
The patient described by Sedwick had an episode of 'fibrillation' soon after discontinuation of amiodarone. A resultant embolic phenomenon was felt to have contributed to the visual loss in the second eye. Our patient, however, had no symptoms other than visual loss and was in sinus rhythm. The half-life of amiodarone is approximately 40 days (range 20-107 days) and that of its desethyl derivative even 10nger. 8•9 Could this explain the visual loss in the second eye despite discontinuing the drug immediately? A serum amiodarone level would have ruled out toxicity although it does not have a predictive power for the occurrence of side effects. 9 It is not clear which patients are more susceptible to optic nerve damage following use of amiodarone. Advanced age, renal failure, diabetes mellitus and alcoholism may be risk factors. l O There appears to be no correlation with either the duration of therapy, daily dose or blood levels of amiodarone.3 Vitamin E (alpha tocopherol) was able to reduce amiodarone and desethylamiodarone toxicity in human cell cultures. ll This raises the hope that the side-effects of amiodarone can be prevented or reversed by the administration of alpha-tocopherol.
The cause-effect relationship between amiodarone and AION remains debatable. In a study of 447 patients taking amiodarone, Feiner et al. 12 calculated the incidence of amiodarone-induced AION to be 1.76% during the preceding 10 years versus 0.3% in patients over 50 years not taking amiodarone. Anterior ischaemic optic neuropathy secondary to previously undiagnosed accelerated hypertension can present to the ophthalmologist. We report such a case in which the anterior ischaemic optic neuropathy reversed following prompt treatment of the hypertension.
Case r ep ort
A 41-year-old man presented to casualty with a 2 h history of reduced vision in the right eye. There were no associated symptoms and no past medical history of note. There was a history of moderate alcohol consumption and a cigarette smoking habit of 30 per day.
Examination revealed a right visual acuity of hand movements, a right relative afferent pupillary defect and the presence of right optic disc oedema. The left visual acuity was 6/6 and fundoscopy revealed a cotton wool spot with a nerve fibre layer haemorrhage (Fig. 1) . There was marked bilateral arteriolar narrowing. The blood pressure was recorded at 220/150 mmHg and the advice of a physician was sought for further investigation and management.
Following treatment with sublingual nifedipine 10 mg the blood pressure fell to 160/110 mmHg. The following morning the right visual acuity had improved to 6/9. 
